(TGTX) TG Therapeutics - Ratings and Ratios

TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for B-cell mediated diseases. The companys lead product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. Beyond BRIUMVI, the companys pipeline includes Ublituximab IV, a glycoengineered anti-CD20 monoclonal antibody in development for relapsing MS; TG-1701, an orally available, covalently bound Brutons tyrosine kinase (BTK) inhibitor with high selectivity; and TG-1801, a bispecific CD47 and CD19 antibody. The company also maintains a robust research pipeline and has established strategic partnerships with entities such as LFB Biotechnologies, GTC Biotherapeutics, and Jiangsu Hengrui Medicine Co., among others, to advance its therapeutic programs.

TG Therapeutics has a market capitalization of $6.03 billion, with a trailing P/E ratio of 256.07 and a forward P/E of 26.39, indicating high valuations relative to earnings. The stock is trading at $40.30, with a 20-day SMA of $38.19, suggesting short-term bullish momentum. However, the high P/B ratio of 25.93 and P/S ratio of 18.34 signal premium valuations. The companys return on equity (RoE) stands at 10.52%, reflecting moderate profitability. Over the next three months, the stock is likely to experience volatility influenced by technical resistance levels and potential pipeline updates. The Average True Range (ATR) of 2.53 suggests moderate price fluctuations, while the 20-day average volume of 2.75 million shares indicates consistent trading activity. Fundamental catalysts, such as clinical trial results or partnership developments, could drive near-term price movements.